The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
NRXS · Healthcare · Narrow moat
On the watchlist
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
MEHA · Healthcare · Narrow moat
Wonderful & reasonably priced
The returnsOnCapital component abstained: Not enough years of ROIC data to score returns on capital. The other four 20% weights were renormalized over the scored 80%.
| Measure | NRXS | GYRE | MEHA | ZBH |
|---|---|---|---|---|
| Moat Score (0–100) | 64 (highest) | 64 (highest) | 64 (highest) | 64 (highest) |
| Methodology version | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 | moat-index@2.0.0 |
| Business trend | 57 | 68 (highest) | 66 | 58 |
| Pricing power | 100 (highest) | 100 (highest) | 90 | 100 (highest) |
| Returns on capital | — | 9 (highest) | — | 6 |
| Balance-sheet safety | 55 | 100 (highest) | 55 | 100 (highest) |
| Capital discipline | 44 | 44 | 44 | 55 (highest) |
| Price vs. high estimate | No price data | 1054% above high estimate | 93% below high estimate (largest discount to high estimate) | Around the high estimate |
| Market cap | $74.7M | $553.4M | $93523 | $17.4B |
| Moat tier | Narrow moat | Narrow moat | Narrow moat | Narrow moat |
| Filings as of | FY2025 | FY2025 | FY2025 | FY2025 |